DoctoRx

Special situations, growth at reasonable price, value, micro-cap
DoctoRx
Special situations, growth at reasonable price, value, micro-cap
Contributor since: 2013
Amgen Beats And Raises, The Street Yawns: An Analysis
Could Celgene's PE Be Headed To The Dreaded Gilead Zone?
Amgen: A Critical Review (Part 2 Of 2)
Why I Lowered My Fair Value Estimate For Amgen (Part 1 Of 2)
Biotechs Blast Off: Could The 1999 Scenario Be In Play?